{"organizations": [], "uuid": "b92493ef57a7ce6a657d388a07eec674ac2881e2", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "uk.reuters.com", "main_image": "https://s2.reutersmedia.net/resources/r/?m=02&d=20180501&t=2&i=1257307220&w=1200&r=LYNXMPEE4021E", "site_section": "http://feeds.reuters.com/Reuters/UKBusinessNews?format=xml", "section_title": "Reuters: Business News", "url": "https://uk.reuters.com/article/us-pfizer-results/pfizers-quarterly-profit-rises-14-percent-idUKKBN1I23EI", "country": "US", "domain_rank": 408, "title": "Pfizer's quarterly profit rises 14 percent", "performance_score": 0, "site": "reuters.com", "participants_count": 0, "title_full": "", "spam_score": 0.0, "site_type": "news", "published": "2018-05-01T13:56:00.000+03:00", "replies_count": 0, "uuid": "b92493ef57a7ce6a657d388a07eec674ac2881e2"}, "author": "", "url": "https://uk.reuters.com/article/us-pfizer-results/pfizers-quarterly-profit-rises-14-percent-idUKKBN1I23EI", "ord_in_thread": 0, "title": "Pfizer's quarterly profit rises 14 percent", "locations": [], "entities": {"persons": [{"name": "sai sachin ra", "sentiment": "none"}, {"name": "akankshita mukhopadhyay", "sentiment": "none"}], "locations": [{"name": "prevnar", "sentiment": "none"}, {"name": "new york", "sentiment": "none"}, {"name": "u.s.", "sentiment": "none"}, {"name": "bengaluru", "sentiment": "none"}], "organizations": [{"name": "pfizer", "sentiment": "negative"}, {"name": "reuters staff", "sentiment": "none"}, {"name": "pfizer inc", "sentiment": "none"}, {"name": "thomson reuters", "sentiment": "none"}, {"name": "reuters", "sentiment": "none"}, {"name": "thomson reuters i/b/e/s. pfizer", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "May 1, 2018 / 10:54 AM / Updated 22 minutes ago Pfizer tops profit estimates, driven by Prevnar sales Reuters Staff 1 Min Read\n(Reuters) - Pfizer Inc’s ( PFE.N ) quarterly profit topped Wall Street forecasts, driven by stronger-than-expected sales of pneumonia vaccine Prevnar. FILE PHOTO: The Pfizer logo is seen at their world headquarters in New York April 28, 2014. REUTERS/Andrew Kelly/File Photo\nThe largest U.S. drugmaker said on Tuesday Prevnar recorded sales of $1.38 billion in the first quarter of 2018. Analysts on average had expected sales of $1.37 billion, according to Thomson Reuters I/B/E/S.\nPfizer’s net profit rose to $3.56 billion or 59 cents per share, from $3.12 billion or 51 cents per share a year earlier.\nExcluding one-time items, the company earned 77 cents per share, topping estimates of 74 cents, according to Thomson Reuters I/B/E/S.\nTotal revenue rose 1 percent to $12.91 billion. Analysts had expected $13.13 billion.\nPfizer shares fell 0.9 percent to $36.28 in premarket trading on Tuesday. Reporting by Akankshita Mukhopadhyay in Bengaluru; Editing by Sai Sachin Ravikumar", "external_links": [], "published": "2018-05-01T13:56:00.000+03:00", "crawled": "2018-05-01T14:26:22.033+03:00", "highlightTitle": ""}